AbbVie/InterMune must show 'irreparable' harm from data disclosure, says top EU court
This article was originally published in SRA
Efforts by AbbVie and InterMune to prevent the European Medicines Agency from disclosing clinical trial data on their products Humira and Esbriet have hit a hurdle after the EU's highest court set aside the interim measures granted to the companies by the General Court earlier this year1-3.
You may also be interested in...
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.
At current rates, not enough coronavirus vaccines will be manufactured in 2021 or even 2022 to meet global demand or achieve global population immunity, according to a new dataset that monitors vaccine supply agreements around the world.